Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acenocoumarol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VKORC1 known ✓ | Q9BQB6 | 3/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 5/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | ALB | P02768 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.77 |
| ▸ | PCSK7 | Q16549 | 1/20 | 0.77 |
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | RECQL | P46063 | 1/20 | 0.71 |
| ▸ | GALK1 | P51570 | 1/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acenocoumarol SCHEMBL33543 | 1.00 | CYP2C9 (1.00) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 | |
| Acenocoumarol SCHEMBL27497093 | 1.00 | CYP2C9 (1.00) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 | |
| Acenocoumarol SCHEMBL14662100 | 0.99 | CYP2C9 (0.98) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 | |
| Acenocoumarol SCHEMBL28086238 | 0.95 | CYP2C9 (0.90) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 | |
| SCHEMBL11700745 | 0.89 | CYP2C9 (0.81) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 | |
| Phenprocoumon SCHEMBL28142123 | 0.89 | CYP2C9 (0.79) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 | |
| Warfarin SCHEMBL29400364 | 0.87 | CYP2C9 (1.00) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 | |
| Warfarin SCHEMBL662875 | 0.87 | CYP2C9 (1.00) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 | |
| Warfarin SCHEMBL4439794 | 0.87 | CYP2C9 (1.00) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 | |
| Warfarin SCHEMBL3689 | 0.87 | CYP2C9 (1.00) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591603-B2 | Aptamers specific for TLR-4 and uses thereof | APTATARGETS, S.L. (ES) | 2023-02-28 | — | — | US | claimed |
| EP-4716745-A1 | NEW TLR-4 ANTAGONIST APTAMERS | Merck Patent GmbH (DE) | 2026-04-01 | — | — | EP | disclosed |
| WO-2025034239-A1 | NATURAL FORMULATIONS TO REDUCE CPD LEVELS | YALE UNIVERSITY (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2024240750-A1 | NEW TLR-4 ANTAGONIST APTAMERS | APTATARGETS, S.L. (ES) | 2024-11-28 | — | — | WO | disclosed |
| US-12148535-B2 | Incrementally optimized pharmacokinetic and pharmacodynamic model | KONINKLIJKE PHILIPS N.V. (NL) | 2024-11-19 | — | — | US | disclosed |
| US-20240192231-A1 | MARKERS FOR THE DIAGNOSIS OF LARGE VESSEL OCCLUSION | SERVICIO ANDALUZ DE SALUD (ES) | 2024-06-13 | — | — | US | disclosed |
| CN-113493449-B | NO donor coumarin furazan conjugate and pharmaceutical application thereof | 复旦大学 | 2024-04-30 | — | — | CN | disclosed |
| CN-117933422-A | Fair federal learning method based on contribution income cooperative balance | 河北工业大学 | 2024-04-26 | — | — | CN | disclosed |
| US-20240100013-A1 | SOTAGLIFLOZIN FOR IMPROVING LEFT ATRIAL FUNCTION | LEXICON PHARMACEUTICALS, INC. (US) | 2024-03-28 | — | — | US | disclosed |
| EP-4323772-A1 | MARKERS FOR THE DIAGNOSIS OF LARGE VESSEL OCCLUSION | Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (ES) | 2024-02-21 | — | — | EP | disclosed |
| US-20220381794-A1 | METHOD FOR SELECTING A PATIENT FOR A REPERFUSION THERAPY | FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA (ES) | 2022-12-01 | — | — | US | disclosed |
| WO-2022219040-A1 | MARKERS FOR THE DIAGNOSIS OF LARGE VESSEL OCCLUSION | FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA (ES) | 2022-10-20 | — | — | WO | disclosed |
| CN-115087665-A | Engineered platelets for targeted delivery of therapeutic agents | JPV01有限公司 | 2022-09-20 | — | — | CN | disclosed |
| EP-4041199-A1 | ESSENTIALLY SODIUM-FREE EFFERVESCENT SOLID PHARMACEUTICAL COMPOSITIONS | Intas Pharmaceuticals Ltd. (IN) | 2022-08-17 | — | — | EP | disclosed |
| US-20220233570-A1 | TREATMENT OF ISCHEMIC STROKE WITH APTAMERS TARGETING TLR-4 | APTATARGETS, S.L. (ES) | 2022-07-28 | — | — | US | disclosed |
| US-20220233572-A1 | TREATMENT OF TLR-4 MEDIATED DISEASES AND CONDITIONS WITH APTAMERS TARGETING TLR-4 | APTATARGETS, S.L. (ES) | 2022-07-28 | — | — | US | disclosed |
| US-20220226368-A1 | ESSENTIALLY SODIUM-FREE EFFERVESCENT SOLID PHARMACEUTICAL COMPOSITIONS | INTAS PHARMACEUTICALS LIMTED (IN) | 2022-07-21 | — | — | US | disclosed |
| WO-2022144465-A1 | SOTAGLIFLOZIN FOR IMPROVING LEFT ATRIAL FUNCTION | Charité-Universitätsmedizin Berlin (DE) | 2022-07-07 | — | — | WO | disclosed |
| EP-3969911-A2 | METHOD FOR SELECTING A PATIENT FOR A REPERFUSION THERAPY | Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (ES) | 2022-03-23 | — | — | EP | disclosed |
| EP-3969011-A1 | TREATMENT OF TLR-4 MEDIATED DISEASES AND CONDITIONS WITH APTAMERS TARGETING TLR-4 | Aptatargets, S.L. (ES) | 2022-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220233572-A1 | TREATMENT OF TLR-4 MEDIATED DISEASES AND CONDITIONS WITH APTAMERS TARGETING TLR-4 | TLR9, TLR4, TLR3 | VKORC1 4784/4885CYP2C9 4828/4885NR1I2 3250/4885 |
| US-20220233570-A1 | TREATMENT OF ISCHEMIC STROKE WITH APTAMERS TARGETING TLR-4 | TLR9, TLR3, TLR4 | VKORC1 4714/4885CYP2C9 4826/4885NR1I2 3250/4885 |
| US-20240100013-A1 | SOTAGLIFLOZIN FOR IMPROVING LEFT ATRIAL FUNCTION | SLC5A2, SLC5A1, GLP1R | VKORC1 1169/4885CYP2C9 1487/4885NR1I2 2717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.